Please login to the form below

Not currently logged in
Email:
Password:

stem cell therapy

This page shows the latest stem cell therapy news and features for those working in and with pharma, biotech and healthcare.

Vertex eyes type 1 diabetes cure with biotech acquisition

Vertex eyes type 1 diabetes cure with biotech acquisition

We are excited to work with the talented scientists at Semma to build on their significant progress toward providing effective and potentially curative cell therapy options for people living with type ... Following the acquisition of Semma, Vertex is

Latest news

More from news
Approximately 3 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The analysts predict the drug will be priced at around $550,

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel),

  • Pharma deals continue to slide Pharma deals continue to slide

    This referred to the CAR-T therapy, Kymriah, from Novartis for treating a form of acute lymphoblastic leukaemia in children and young adults. ... 425 (upfront 80). Calimmune (US). CSL (AU). Company acquisition. Preclinical haematopoietic stem cell

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    Mock assessment of a CAR-T therapy. The hypothetical CAR-T therapy was tested in two different profiles: as a bridge to haematopoietic stem cell transplantation or as a curative therapy. ... If so, how much of the per-patient price could the cell therapy

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Stem cell therapy for HF is currently being led by the likes of Bioheart (recently renamed US Stem Cell), which has muscle stem cell therapy candidate Myocell in a phase III ... trial; Mesoblast/Teva with allogenic mesenchymal stem cell therapy Neofuse;

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Dr Jay Stout moves from Merck to SanBio Dr Jay Stout moves from Merck to SanBio

    In this role, he is responsible for all production-related operations, including clinical cell preparation, final quality assurance and process development. ... He is perhaps the individual with the greatest experience in the world in manufacturing

  • Plasticell names Aaron Chuang as chief scientific officer Plasticell names Aaron Chuang as chief scientific officer

    Chuang was an industrial advisor on high profile stem cell initiatives including UK Stem Cell Initiative, UK Cell Therapy Catapult and the California Institute of Regenerative Medicine. . ... He was also prominent in establishing GSK's alliance with the

  • ReNeuron makes shifts and additions to senior team ReNeuron makes shifts and additions to senior team

    Including Sharon Grimster being named as general manager for Wales. UK-based stem cell therapy company ReNeuron has announced a number of board and senior management changes. ... Dr Randolph Corteling has been promoted to head of research from his

  • ReNeuron appoints new CEO ReNeuron appoints new CEO

    Olav Hellebø joins from Clavis Pharma. UK-based stem cell therapy company ReNeuron Group has appointed Olav Hellebø as its new CEO with immediate effect. ... ReNeuron's stem cell therapy candidates, will be the best way to ensure as many patients as

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Solaris Health looks at the gene therapy revolution

    And every new therapy will have its own specific challenges depending on the disease it is targeting. ... As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the ... The biotech creates ‘off-the-shelf’ cell-based therapies,

  • How do you define a biotech company?

    ReNeuron, a leading, clinical-stage stem cell business.

  • Healthcare in the Digital Age

    Exciting developments in immunotherapy and oncology, and huge strides in gene and stem-cell therapy are matched by powerhouse collaborations between academia and industry that point to a golden age for

  • Blue Latitude Health

    Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. ... Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics